BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nonoshita T, Shioyama Y, Nakamura K, Nakashima T, Ohga S, Yoshitake T, Ohnishi K, Terashima K, Asai K, Honda H. Concurrent chemoradiotherapy with S-1 for T2N0 glottic squamous cell carcinoma. J Radiat Res 2010;51:481-4. [PMID: 20601829 DOI: 10.1269/jrr.09134] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Higashino M, Kawata R, Lee K, Nishikawa S, Ichihara S, Uesugi Y. Radiotherapy concurrent with S-1 and radiotherapy alone for T2N0 glottic carcinoma: a retrospective comparative study. Auris Nasus Larynx 2014;41:364-8. [PMID: 24656970 DOI: 10.1016/j.anl.2014.02.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
2 Kitani Y, Kubota A, Furukawa M, Sato K. Prognostic factors for local control in patients receiving radiation therapy for early glottic cancer: anterior commissure involvement and effect of chemoradiotherapy. Eur Arch Otorhinolaryngol 2016;273:1011-7. [DOI: 10.1007/s00405-015-3579-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
3 Kimura K, Itoh Y, Okada T, Kubota S, Kawamura M, Nakahara R, Oie Y, Kozai Y, Takase Y, Tsuzuki H, Nishio N, Hiramatsu M, Fujimoto Y, Mizutani T, Hirakawa A, Naganawa S. Study Protocol: Prospective Study of Concurrent Chemoradiotherapy with S-1 and Hypofractionated Radiotherapy for Outpatients with Early Glottic Squamous Cell Carcinomas. Asian Pac J Cancer Prev 2018;19:1195-9. [PMID: 29801401 DOI: 10.22034/APJCP.2018.19.5.1195] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Masuda M, Matsuo M, Aso T, Kiyohara H, Rikimaru F, Kunitake N, Higaki Y. Utility of algorithm-based chemoradioselection in the treatment for advanced hypopharyngeal carcinoma. Head Neck 2015;37:1290-6. [PMID: 24816950 DOI: 10.1002/hed.23759] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
5 Hendriksma M, Ruler MAPV, Verbist BM, Jong MA, Langeveld TPM, Benthem PPGV, Sjögren EV. Survival and Prognostic Factors for Outcome after Radiotherapy for T2 Glottic Carcinoma. Cancers (Basel) 2019;11:E1319. [PMID: 31500162 DOI: 10.3390/cancers11091319] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
6 Shih HS, Jhou HJ, Ou YH, Liu YT, Kor CT, Chen AW, Chen MK. The Efficacy and Adverse Events in Patients with Head and Neck Cancer Following Radiotherapy Combined with S-1 Therapy: A Meta-Analysis. Cancers (Basel) 2021;13:2971. [PMID: 34199326 DOI: 10.3390/cancers13122971] [Reference Citation Analysis]
7 Takase Y, Itoh Y, Ohtakara K, Kawamura M, Ito J, Oie Y, Ono T, Sasaki Y, Nishida A, Naganawa S. Early glottic cancer treatment with concurrent chemoradiotherapy with once-daily orally administered S-1. Nagoya J Med Sci 2021;83:251-8. [PMID: 34239173 DOI: 10.18999/nagjms.83.2.251] [Reference Citation Analysis]
8 Nakashima T, Yasumatsu R, Toh S, Shiratsuchi H, Kamitani T, Shioyama Y, Nakamura K, Komune S. Advanced maxillary sinus cancer treated with concurrent chemoradiotherapy with intra-arterial cisplatin/docetaxel and oral s-1: own experience and literature review. Case Rep Oncol 2011;4:492-8. [PMID: 22114575 DOI: 10.1159/000332759] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
9 Masuda M, Wakasaki T, Toh S, Uchida Y, Rikimaru H, Kunitake N, Higaki Y. Utility of chemoradioselection for the optimization of treatment intensity in advanced hypopharyngeal and laryngeal carcinoma. Mol Clin Oncol 2017;7:965-70. [PMID: 29285357 DOI: 10.3892/mco.2017.1466] [Reference Citation Analysis]
10 Taguchi T, Takahashi M, Nishimura G, Shiono O, Komatsu M, Sano D, Sakuma Y, Tanigaki Y, Kubota A, Taguri M, Hata M, Oridate N. Phase II study of concurrent chemoradiotherapy with S-1 in patients with stage II (T2N0M0) squamous cell carcinoma of the Pharynx or Larynx. Jpn J Clin Oncol 2014;44:1158-63. [PMID: 25267992 DOI: 10.1093/jjco/hyu154] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
11 Yokota T, Hamauchi S, Shirasu H, Onozawa Y, Ogawa H, Onoe T, Onitsuka T. How Should We Approach Locally Advanced Squamous Cell Carcinoma of Head and Neck Cancer Patients Ineligible for Standard Non-surgical Treatment? Curr Oncol Rep 2020;22:118. [PMID: 32945988 DOI: 10.1007/s11912-020-00984-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Nakata K, Sakata K, Someya M, Miura K, Hayashi J, Hori M, Takagi M, Himi T, Kondo A, Hareyama M. Phase I study of oral S-1 and concurrent radiotherapy in patients with head and neck cancer. J Radiat Res. 2013;54:679-683. [PMID: 23292146 DOI: 10.1093/jrr/rrs133] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
13 Khan MK, Koyfman SA, Hunter GK, Reddy CA, Saxton JP. Definitive radiotherapy for early (T1-T2) glottic squamous cell carcinoma: a 20 year Cleveland Clinic experience. Radiat Oncol 2012;7:193. [PMID: 23164282 DOI: 10.1186/1748-717X-7-193] [Cited by in Crossref: 49] [Cited by in F6Publishing: 13] [Article Influence: 4.9] [Reference Citation Analysis]